Diagonal Bio publishes interim report for the third quarter of 2025

Summary of the interim report for the third quarter of 2025

2025-07-01 — 2025-09-30 ( July-September 2025 )

• Net sales amounted to 45 KSEK (0 KSEK), capitalised development contributed with 238 KSEK

(248 KSEK), and other operating income amounted to 0 KSEK (0 KSEK).

• The net loss amounted to -2 042 KSEK (-1 242 KSEK).
• Operating profit per net weighted average share amounted to -0.001 SEK (0 SEK).
• Cash flow during the third quarter amounted to -1 002 KSEK (-2 428 KSEK).
• Cash and cash equivalents at the end of the period amounted to 1 737 KSEK (1 730 KSEK).

Significant events during the third quarter of 2025

• July 7, Diagonal Bio announced that the Company had filed a patent
  application with the Swedish Intellectual Property Office (PRV), covering
  a novel computational method that significantly improves the design
  of LAMP primers – a critical component in molecular analysis.
• August 20, Diagonal Bio announced that the Company had received
  a confirmation from the Japanese Patent Office that the patent
  application regarding “A method of measuring the ph of a sample”
  (no.: JP7655939) had been granted in Japan.
• September 18, Diagonal Bio announced that Stall Courant, one of
  Sweden’s leading international horse trotting and breeding stables,
  had placed an order for LAMPLify. The stable is managed by the
  internationally renowned trotting trainer Sabine Kagebrant and home
  to more than 125 horses. Stall Courant chose a 36-month leasing
  agreement through Svea Bank, which shows both confidence in the
  technology and a long-term commitment.
• September 23, Diagonal Bio announced the expansion of its equine
  testing panel to include the detection of Equine Herpesvirus type 2
  (EHV-2). This broadens the Company’s product portfolio and addresses
  an unmet need in equine health.

Significant events since 30 September 2025

• October 3, Diagonal Bio announced that the Company had initiated
  a collaboration with Swedish Veterinary Agency (SVA) to support
  the evaluation of testing for equine coronavirus in nasal swabs. The
  project runs during October and is carried out under the supervision
  of Johanna Lindahl, State veterinarian and Professor in global infection
  biology.
• October 13, Diagonal Bio announced the launch of its new website,
  marking an important step in the implementation of the Company’s
  strategy to strengthen its commercial presence and focus on the
  animal health market, particularly within the equine segment.

For additional information about Diagonal Bio, please contact:
Karin Wehlin, CEO
Phone: +46 70 305 24 88
E-mail: kw@diagonalbio.com

About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio’s patented technology can also be used for the less regulated market segments via LAMPlify®.